An Open-label, Single-sequence, Four-treatment Period Study to Evaluate Pharmacokinetic and Pharmacodynamic Interactions Between E5501 and Verapamil, and E5501 and Cyclosporine, Known P-glycoprotein Inhibitors in Healthy Subjects.

Trial Profile

An Open-label, Single-sequence, Four-treatment Period Study to Evaluate Pharmacokinetic and Pharmacodynamic Interactions Between E5501 and Verapamil, and E5501 and Cyclosporine, Known P-glycoprotein Inhibitors in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2012

At a glance

  • Drugs Avatrombopag (Primary) ; Ciclosporin; Verapamil
  • Indications Atrial fibrillation; Ischaemic heart disorders; Paroxysmal supraventricular tachycardia; Psoriasis; Rheumatoid arthritis; Supraventricular tachycardia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 May 2012 Actual patient number 36 added according to ClinicalTrials.gov.
    • 18 May 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 18 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top